EPL
NRIX icon

EDBI Pte Ltd’s Nurix Therapeutics NRIX Stock Holding History

EDBI Pte Ltd’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,442
Closed -$97K – 22
2022
Q3 		$97K Hold
7,442
– – 0.1% 22
2022
Q2 		$94K Hold
7,442
– – 0.09% 21
2022
Q1 		$104K Hold
7,442
– – 0.07% 19
2021
Q4 		$215K Buy
+7,442
New +$226K 0.12% 17

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

EDBI Pte Ltd's NRIX Position: Q4 2022 in Review

EDBI Pte Ltd sold out of Nurix Therapeutics (NRIX) in Q4 2022, closing a stake of 7,442 shares — an estimated $97K sold.

EDBI Pte Ltd first reported a position in NRIX in Q4 2021 and held it in 4 quarters. The position peaked at $215K in Q4 2021. 118 funds tracked by Wall St. Rank hold NRIX as of Q4 2022.

  • EDBI Pte Ltd reported no remaining Nurix Therapeutics position as of Q4 2022 after selling out during the quarter.
  • EDBI Pte Ltd sold 7,442 Nurix Therapeutics shares in Q4 2022, an estimated $97K.
  • EDBI Pte Ltd first reported a position in Nurix Therapeutics in Q4 2021 and held it in 4 quarters.
  • EDBI Pte Ltd's Nurix Therapeutics position peaked at $215K in Q4 2021.
  • 118 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2022.

Based on EDBI Pte Ltd's 13F filing for Q4 2022, filed 30 Jan 2023.